By Mill Chart
Last update: Feb 27, 2024
QUEST DIAGNOSTICS INC (NYSE:DGX) has caught the attention of dividend investors as a stock worth considering. NYSE:DGX excels in profitability, solvency, and liquidity, all while providing a decent dividend. Let's delve into the details.
ChartMill provides a Dividend Rating for every stock, ranging from 0 to 10. This rating assesses various dividend aspects, including yield, growth, and sustainability. NYSE:DGX earns a 7 out of 10:
ChartMill employs a unique Health Rating system for all stocks. This rating, ranging from 0 to 10, is determined by analyzing various liquidity and solvency ratios. For NYSE:DGX, the assigned 5 for health provides valuable insights:
Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NYSE:DGX has achieved a 7:
More Best Dividend stocks can be found in our Best Dividend screener.
For an up to date full fundamental analysis you can check the fundamental report of DGX
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
QUEST DIAGNOSTICS INC
NYSE:DGX (4/18/2024, 7:04:00 PM)
After market: 125.91 0 (0%)125.91
-1.07 (-0.84%)
Uncovering Dividend Opportunities with QUEST DIAGNOSTICS INC (NYSE:DGX).
/PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and Broad Clinical Labs, the world expert in whole genome...
/PRNewswire/ -- A blood test that analyzes levels of amyloid proteins by highly sensitive mass spectrometry could help physicians establish that Alzheimer's...
/PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report first quarter 2024...
/PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President and...
/PRNewswire/ -- Pack Health, a Quest Diagnostics (NYSE: DGX) company specializing in patient engagement, and Instacart (NASDAQ: CART), the leading grocery...
/PRNewswire/ -- Freenome, a biotechnology company developing blood tests for early cancer detection, announced the addition of $254 million from new and...
/PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today announced the launch of MelaNodal...